Model‐Based Prediction of Clinically Relevant Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation
Platelet reconstitution after allogeneic hematopoietic cell transplantation (allo-HCT) is heterogeneous and influenced by various patient- and transplantation-related factors, associated with poor prognoses for poor graft function (PGF) and isolated thrombocytopenia. Tailored interventions could improve the outcome of patients with PGF and post-HCT thrombocytopenia. To provide individual predictions of 180-day platelet counts from early phase data, we developed a model of long-term platelet reconstitution after allo-HCT. A large cohort (n = 1949) of adult patients undergoing their first allo-HCT was included. Real-world data from 1,048 retrospective patients were used for non-linear mixed-effects model development. Bayesian forecasting was used to predict platelet-time profiles for 518 retrospective and 383 prospective patients during internal and external model validation, respectively. Thrombocytopenia was defined as mean platelet count < 75 × 10<sup>9</sup>/L, derived from the last 12 platelet measurements within the first 180 days post-HCT. Thrombocytopenia affected 37% of all patients and was associated with significantly reduced overall survival (P-value < 0.0001). On days +7, +14, +21, and +28, the developed model achieved areas under the receiver-operating characteristic of ≥ 0.68, ≥ 0.75, ≥ 0.78, and 0.81 for the prediction of post-HCT thrombocytopenia, respectively, with anti-thymocyte globulin, donor relation, and total protein measurements representing prognostic markers for post-HCT platelet kinetics. A publicly accessible web-based demonstrator of the model was established (https://hsct.precisiondosing.de). In summary, the developed model predicts individual platelet counts from day +28 post-HCT adequately, utilizing internal and external datasets. The web-based demonstrator provides a basis to implement model-based predictions in clinical practice and to confirm these findings in future clinical studies.
Authors
- Jürgen Rissland
- Stephan Kiefer (ORCID: https://orcid.org/0000-0001-6840-6240)
- Ulf Schwarz
- Joerg Thomas Bittenbring (ORCID: https://orcid.org/0000-0003-3864-8315)
- Dietrich W. Beelen (ORCID: https://orcid.org/0000-0001-5050-220X)
- Katharina M. Götz (ORCID: https://orcid.org/0009-0005-8963-4329)
- Dominik Selzer (ORCID: https://orcid.org/0000-0002-4126-0816)
- Christian Brossette
- Katharina Och
- Norbert M. Graf (ORCID: https://orcid.org/0000-0002-2248-323X)
- Sigrun Smola (ORCID: https://orcid.org/0000-0003-3289-6545)
- Lisa Eisenberg (ORCID: https://orcid.org/0000-0002-1041-7948)
- Dominic Kaddu‐Mulindwa (ORCID: https://orcid.org/0000-0001-8832-252X)
- Amin T. Turki (ORCID: https://orcid.org/0000-0003-1347-3360)
- Matthias Schwab (ORCID: https://orcid.org/0000-0002-9984-075X)
- Simeon Rüdesheim (ORCID: https://orcid.org/0000-0002-5741-2511)
- Kerstin Rohm (ORCID: https://orcid.org/0000-0001-7171-4308)
- Gabriele Weiler (ORCID: https://orcid.org/0000-0002-3052-8776)
- Nico Pfeifer (ORCID: https://orcid.org/0000-0002-4647-8566)
- Thorsten Lehr (ORCID: https://orcid.org/0000-0002-8372-1465)
- Jochen Rauch (ORCID: https://orcid.org/0000-0001-9597-3603)
- Claudia Riede
- Yvonne Braun (ORCID: https://orcid.org/0000-0002-8193-5777)
- Stefan Theobald
Institutions
- University Hospitals of the Ruhr-University of Bochum (DE)
- Essen University Hospital (DE)
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
- Averbis (Germany) (DE)
- Fraunhofer Institute for Biomedical Engineering (DE)
- University of Tübingen (DE)
- Ruhr University Bochum (DE)
- Saarland University (DE)
Publication Details
- Journal
- Clinical Pharmacology & Therapeutics
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1002/cpt.3580
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- HORIZON EUROPE Framework Programme